Delivery Order SPE2DB24D3015-SPE2DB26FFWRN
- Not listed
- The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 14, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $12,330.68 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors on September 18, 2025, with an ultimate completion date of October 9, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus, representing a specialty...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on September 8, 2025, with completion targeted for September 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and lupus nephritis, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on August 28, 2025, with completion anticipated by September 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $55,488.06 for Benlysta 200 mg/ml auto-injectors on September 17, 2025, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on July 17, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody treatment indicated for systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units on September 11, 2025, with an ultimate completion date of October 2, 2025. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,082.67 and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB26FFWRNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on October 15, 2025, with completion scheduled for November 5, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody immunosuppressant used to treat systemic lupus erythematosus, representing a specialized pharmaceutical product within the company's broader federal medical supply portfolio. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains an extensive contract portfolio with DLA supporting military and veteran healthcare systems through the supply of brand-name and generic medications, vaccines, and specialized medical commodities. The company's status as a prime contractor on this substantial IDC vehicle demonstrates its established capability to fulfill federal pharmaceutical procurement requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 10/15/25 |